Pharmacological Inhibition of the Vacuolar ATPase in Bloodstream-Form Trypanosoma brucei Rescues Genetic Knockdown of Mitochondrial Gene Expression

Citation for published version:
Schaffner-Barbero, C, Miskinyte, M, Grewal, JS & Schnaufer, A 2018, 'Pharmacological Inhibition of the Vacuolar ATPase in Bloodstream-Form Trypanosoma brucei Rescues Genetic Knockdown of Mitochondrial Gene Expression' Antimicrobial Agents and Chemotherapy, vol. 62, no. 9. DOI: 10.1128/AAC.02268-17

Digital Object Identifier (DOI):
10.1128/AAC.02268-17

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published In:
Antimicrobial Agents and Chemotherapy

Publisher Rights Statement:
© 2018 Schaffner-Barbero et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Pharmacological Inhibition of the Vacuolar ATPase in Bloodstream-Form *Trypanosoma brucei* Rescues Genetic Knockdown of Mitochondrial Gene Expression

Claudia Schaffner-Barbero,a Migla Miskinyte,a Jaspreet Singh Grewal,b Achim Schnaufera

aInstitute of Immunology & Infection Research, University of Edinburgh, Edinburgh, United Kingdom
bDepartment of Biology, Centre for Immunology and Infection, University of York, York, United Kingdom

ABSTRACT Trypanosomatid parasites cause diseases in humans and livestock. It was reported that partial inhibition of the vacuolar ATPase (V-ATPase) affects the dependence of *Trypanosoma brucei* on its mitochondrial genome (kinetoplast DNA (kDNA)), a target of the antitrypanosomatid drug isometamidium. Here, we report that V-ATPase inhibition with bafilomycin A1 (BafA) provides partial resistance to genetic knockdown of mitochondrial gene expression. BafA does not promote long-term survival after kDNA loss, but in its presence, isometamidium causes less damage to kDNA.

KEYWORDS F1Fo-ATPase, RNA editing, *Trypanosoma*, V-ATPase, bafilomycin, kDNA, kinetoplast, mitochondria, vacuoles
mitochondrial ATPase function and kDNA dependence in trypanosomes. V-ATPase is essential in *T. brucei*, but sublethal inhibition of the complex by low-efficiency RNAi or with the V-ATPase inhibitor bafilomycin A1 (BafA) permitted survival for at least 3 days in the presence of normally lethal concentrations of ISM (14). The physiological mechanism of compensation remained obscure. We decided to investigate the effects of sublethal concentrations of BafA on kDNA dependence over longer time scales. All methods were performed as described previously (7, 12), unless otherwise specified.

We first investigated whether V-ATPase inhibition affects the dependence of BF *T. brucei* on RNA editing. RNA editing ligase 1 (REL1) is a key component of the *T. brucei* editosome, and its knockdown is lethal (15, 16). Expression of an ATP synthase subunit with an L262P mutation fully rescues from this phenotype (12). If partial inhibition of the V-ATPase by BafA renders cells impervious to kDNA loss, treatment with the drug should also rescue from the growth phenotype observed upon knockdown of REL1.

We used a REL1 conditional knockout cell line (REL1-cKO), where an ectopic copy of the REL1 gene is under the control of a tetracycline (Tet)-inducible promoter and both endogenous REL1 alleles have been deleted (15). After the removal of Tet from the medium, cKO-REL1 cells exhibited a rapid and severe growth defect, with growth ceasing completely after 96 h (Fig. 1A, dashed black curve), and no live cells being visible under the microscope at later time points, as observed before (15). The presence of 8 nM or 10 nM BafA alleviated the growth defect, with cells continuing to proliferate 168 h after Tet removal (Fig. 1A and B, dashed cyan and blue curves and columns, respectively) despite REL1 being below the detection limit in a Western blot assay (Fig. 1C and D; all image acquisitions and analyses were performed digitally with Li-Cor Odyssey or C-DiGit systems). Lower concentrations of BafA did not alleviate the growth defect caused by REL1 depletion (Fig. 1A, green curves), while higher BafA concentrations caused a severe growth defect even in the presence of Tet (Fig. 1A, pink curves). We note that the range of concentrations in which rescue occurred was narrow and varied slightly between experiments and BafA stocks (data not shown). To investigate if BafA affected the knockdown of RNA editing itself, we assessed levels of the F₁F₀-ATPase subunit Tb2. The stability of this protein depends on presence of the kDNA-encoded F₀ subunit α, in that in the absence of functional kDNA (and thus subunit α), the level of Tb2 is substantially reduced (Fig. 1E and F) (17). We found that even in the presence of 8 nM or 10 nM BafA, knockdown of REL1 reduced the levels of Tb2 to at least the same extend as with the loss of kDNA (Fig. 1C). We conclude that the rescue effect provided by BafA appears to reduce dependence on a functional F₁F₀-ATPase, as suggested by Baker et al. (14).

Next, we investigated if treatment with BafA would rescue from cell death caused by kDNA loss, induced either genetically or pharmacologically. To induce kDNA loss genetically, we repressed expression of the TAC102, an essential component of the tripartite attachment complex and thus required for kDNA segregation during cell division (18). As expected, Tet-induced TAC102 knockdown in the published RNAi cell line (18) caused a severe growth defect and kDNA loss (Fig. 2). In contrast to the RNA editing knockdown experiment, however, we did not observe any rescue of either phenotype by incubation with BafA (Fig. 2A and D).

To induce kDNA loss pharmacologically, we treated BF *T. brucei* cells with 0.1 nM ISM. At this concentration, ISM causes kDNA loss but only a very minor growth defect in kDNA-independent cells, as demonstrated by transgenic expression of an F₁ γ-subunit allele with the L262P mutation (Fig. 3A, green triangles and lines; see also reference 7). In the absence of BafA, kDNA-dependent cells showed a severe growth defect, in that cells complete stopped proliferating after 168 h (Fig. 3A, black squares and lines), with few, if any, surviving cells visible by microscopic inspection after 240 h or later. In contrast, in the presence of 10 nM or 15 nM BafA, cells continued to proliferate, albeit at much lower rates (Fig. 3A, blue and orange symbols and lines). The difference in cumulative growth after 313 h (the endpoint of the experiment) was reproducible and statistically significant (Fig. 3B). At 8 nM BafA, the rescue effect was
less pronounced (Fig. 3A, cyan triangles and lines, experiment terminated after 192 h), while 20 nM BafA caused a severe growth defect even in the absence of ISM, as observed before (Fig. 3A and 1A, pink circles and lines, experiment also terminated after 192 h). In contrast to what we had found for genetic induction of kDNA loss, we observed that BafA afforded significant protection from kDNA loss caused by ISM. After 96 h of exposure to ISM, about 70% of the control cells had lost their kDNA, as observed by staining with 4',6-diamidino-2-phenylindole (DAPI) and microscopy (Fig. 3C; O0K1N, cells with 1 nucleus but no kinetoplast). In cultures where we added 10 nM or 15 nM BafA to the growth medium, the fractions of O0K1N cells present at 96 h were reduced to ~50% and ~30%, respectively (Fig. 3C). In cells where a kinetoplast was visible (1K1N cells), quantitation of kDNA by measuring relative fluorescence compared to the...
nucleus confirmed that exposure to ISM for 96 h caused a significant reduction in the amount of organellar DNA, presumably an intermediate stage to complete kDNA loss (Fig. 3D). Incubation with 15 nM BafA ISM provided highly significant protection from this effect (Fig. 3D). Taken together, the experiments with kDNA loss induced genetically or by ISM treatment suggest the following: pharmacological inhibition of the V-ATPase with BafA cannot protect T. brucei from the lethal effects of complete loss of kDNA. Instead, BafA reduces kDNA damage and loss caused by ISM.

Finally, we induced kDNA loss with an alternative pharmacological regime, exposure to 10 nM EtBr. Like ISM, EtBr is a compound from the phenanthridine class that at low concentrations causes kDNA loss but affects growth of kDNA-independent cells only mildly (Fig. 3E, green triangles and lines represent growth of cells expressing a y-subunit with the L262P mutation; see also references 7 and 8). We found that simultaneous incubation with 15 nM BafA resulted in a reproducible rescue from cell death caused by treatment with EtBr (Fig. 3E and F), although the effect was much less pronounced than with ISM, and very few surviving cells were apparent after 168 h (the endpoint of this experiment).

These results pose two important questions. First, why did we observe robust rescue by BafA of growth defects caused by knockdown of RNA editing but not of growth defects caused by inhibition of kDNA maintenance? To our present knowledge, the two processes serve the same goal in BF T. brucei, namely, the production of F1F0 subunit a (12). One potential explanation is that partial inhibition of V-ATPase makes the parasites less dependent on proton pumping by the F1F0-ATPase, for example, by changing the pH balance between cellular compartments, but it does not make the parasites completely independent from it. A similar scenario has been proposed for yeast cells lacking mitochondrial DNA (19). The inducible gene expression system that we used in our study to knock down REL1 is unlikely to achieve complete repression in
FIG 3 (A) Cumulative growth curves for T. brucei BF cells cultured in the absence (filled symbols, solid lines) and presence (open symbols, dashed lines) of 0.1 nM ISM and at various concentrations of BafA. In parallel, a cell line expressing an ATPase subunit-γ allele with the L262P mutation was also grown in the absence of presence of 0.1 nM ISM (green triangles and lines). Each data point is the average of two growth curves; error bars indicate the SD. (B) Comparison of cumulative cell numbers (in panel A) after 313 h. Statistical significance of differences was assessed with the Student unpaired t test; 0.01 \(< P < 0.05\) (*) was for 0 nM BafA + ISM versus 10 nM BafA + ISM; \(P < 0.001\) (**) was for 0 nM BafA + ISM versus 15 nM BafA + ISM. (C) Loss of kDNA (0K1N cells) assessed by DAPI staining and microscopy after 96 h of culturing. Statistical significance of differences was assessed with the Student unpaired t test; 0.01 < \(P < 0.05\) (*) was for the wild type (WT) + ISM 0 nM BafA versus WT + ISM 10 nM BafA or versus WT + ISM 15 nM BafA. (D) The relative amount of kDNA in 1K1N cells after 96 h of culturing was assessed by DAPI staining and quantitation of kinetoplast versus nucleus fluorescence intensity. Statistical significance of differences was assessed with the Mann-Whitney test; \(P < 0.001\) (**) for −ISM 0 nM BafA \((n = 26)\) versus +ISM 0 nM BafA \((n = 35)\); \(P < 0.001\) (**) for +ISM 0 nM BafA versus +ISM 15 nM BafA \((n = 56)\). (E) Cumulative growth curves of T. brucei BF cells cultured in the absence (filled symbols, solid lines) and presence (open symbols, dashed lines) of 10 nM EtBr and at various concentrations of BafA. In parallel, a cell line expressing an ATPase subunit-γ allele with the L262P mutation was also grown in the absence of presence of 10 nM EtBr (green triangles and lines). Each data point is the average from four separate growth curves; error bars indicate the SD. (F) Comparison of cumulative cell numbers (in panel E) after 168 h. Statistical significance of differences was assessed with the Wilcoxon rank sum test; 0.01 < \(P < 0.05\) (*) was for +EtBr 0 nM BafA versus +EtBr 15 nM BafA.
the absence of inducer (20), presumably resulting in some residual expression of REL1 and, consequently, subunit a. In contrast, interference with kDNA maintenance will result in an “all or nothing” response in affected cells, i.e., cells that lose kDNA will completely lose subunit a and F1,F0-ATPase proton-pumping activity. We must note, however, that REL1 in repressed cells was below the detection limit of our Western blot analysis, and F0, subunit Tb2 in these cells was reduced to levels comparable to what we observe in cells depleted of kDNA. Testing this hypothesis will require the development of more sensitive and highly quantitative methods for the detection of intact F1,F0-ATPase. Second, why was BafA more effective in rescuing the cells from the effects of ISM than the related EtBr? Our results provide indirect evidence that V-ATPase inhibition by BafA reduces mitochondrial uptake of ISM. How ISM and EtBr enter the mitochondrion is unknown, although efficient uptake of at least ISM appears to depend on the mitochondrial membrane potential (13). Our results suggest that the mitochondrial uptake mechanisms for ISM and EtBr may not be identical and that V-ATPase inhibition affects uptake of ISM more than uptake of EtBr. Resolving this question will require the development of methods to specifically measure the mitochondrial uptake of these compounds.

In summary, our results indicate complex effects of sublethal inhibition of the V-ATPase on *T. brucei* that affect both the degree of dependence on kDNA-encoded products as well as mitochondrial uptake of kDNA-intercalating trypanocides. Our study corroborates an intriguing link between vacuolar and mitochondrial ATPase function that begs further investigation. Furthermore, we suggest that pharmacological inhibition of V-ATPase function can be a useful research tool in the study of otherwise lethal perturbations of mitochondrial gene expression in BF *T. brucei*, but it should be noted that any experiment will require careful titration of inhibitors.

**ACKNOWLEDGMENTS**

C.S.-B., M.M., and A.S. designed the research, analyzed the data, and wrote the paper; C.S.-B., M.M., and J.S.G. performed the research.

We thank David Horn (University of Dundee) for helpful discussions, Ken Stuart (Center for Infectious Disease Research) for the REL1 antibody, Alena Zikova (Biology Centre, Czech Academy of Sciences, České Budejovice) for the Tb2 antibody, and Torsten Ochsenreiter (University of Bern) for the TAC102 RNA interference (RNAi) cell line and antibody.

This work was supported by Senior Non-Clinical Fellowship MR/L019701/1 from the UK Medical Research Council to A.S.; J.S.G. was supervised by Jeremy C. Mottram (University of York) and supported by research grant MR/K019384 from the UK Medical Research Council to Jeremy C. Mottram.

**REFERENCES**

1. Stuart K, Brun R, Croft S, Fairlamb A, Gürtler RE, McKerrow J, Reed S, Tarleton R. 2008. Kinetoplastids: related protozoan pathogens, different diseases. J Clin Invest 118:1301–1310. https://doi.org/10.1172/JCI33945.

2. Morrison LJ, Vezza L, Rowan T, Hope JC. 2016. Animal African trypanosomiasis: time to increase focus on clinically relevant parasite and host species. Trends Parasitol 32:599–607. https://doi.org/10.1016/j.pt.2016.04.012.

3. Jensen RE, Englund PT. 2012. Network news: the replication of kinetoplast DNA. Ann Rev Microbiol 66:473–491. https://doi.org/10.1146/annurev-micro-092611-150037.

4. Read LK, Lukeš J, Hashimi H. 2016. Trypanosome RNA editing: the complexity of getting U in and taking U out. Wiley Interdiscip Rev RNA 7:33–51. https://doi.org/10.1002/wrna.1313.

5. Aphasizheva I, Aphasizhev R. 2016. U-Insertion/deletion mRNA-editing holoenzyme: definition in sight. Trends Parasitol 32:144–156. https://doi.org/10.1016/j.pt.2015.10.004.

6. Giordani F, Morrison LJ, Rowan TG, De Koning HP, Barrett MP. 2016. The animal trypanosomases and their chemotherapy: a review. Parasitology 143:1862–1889. https://doi.org/10.1017/S0031182016001268.

7. Gould MK, Schnaufer A. 2014. Independence from kinetoplast DNA maintenance and expression is associated with multi-drug resistance in *Trypanosoma brucei* in vitro. Antimicrob Agents Chemother 58: 2925–2928. https://doi.org/10.1128/AAC.00122-14.

8. Roy Chowdhury A, Bakshi R, Wang J, Yildirir G, Liu B, Pappas-Brown V, Tolun G, Griffith JD, Shapiro TA, Jensen RE, Englund PT. 2010. The killing of African trypanosomes by ethidium bromide. PLoS Pathog 6:e1001226. https://doi.org/10.1371/journal.ppat.1001226.

9. Vercesi AE, Docampo R, Moreno SN. 1992. Energization-dependent Ca2+ accumulation in Trypanosoma brucei bloodstream and procyclic trypanomastigotes mitochondria. Mol Biochem Parasitol 56:251–257. https://doi.org/10.1016/0166-6851(92)90174-I.

10. Nolan DP, Voorheis HP. 1992. The mitochondrion in bloodstream forms of *Trypanosoma brucei* is energized by the electrogenic pumping of protons catalysed by the F1,F0-ATPase. Eur J Biochem 209:207–216. https://doi.org/10.1111/j.1432-1033.1992.tb17278.x.

11. Schnaufer A, Clark-Walker GD, Steinberg AG, Stuart K. 2005. The F1-ATP synthase complex in bloodstream stage trypanosomes has an unusual and essential function. EMBO J 24:4029–4040. https://doi.org/10.1038/sj.emboj.7600862.
12. Dean S, Gould MK, Dewar CE, Schnaufer AC. 2013. Single point mutations in ATP synthase compensate for mitochondrial genome loss in trypanosomes. Proc Natl Acad Sci U S A 110:14741–14746. https://doi.org/10.1073/pnas.1305404110.

13. Eze AA, Gould MK, Munday JC, Tagoe DNA, Stelmanis V, Schnaufer A, De Koning HP. 2016. Reduced mitochondrial membrane potential is a late adaptation of Trypanosoma brucei brucei to isometamidium preceded by mutations in the β subunit of the F1Fo-ATPase. PLoS Negl Trop Dis 10: e0004791. https://doi.org/10.1371/journal.pntd.0004791.

14. Baker N, Hamilton G, Wilkes JM, Hutchinson S, Barrett MP, Horn D. 2015. Vacular ATPase depletion affects mitochondrial ATPase function, kinetoplast dependency, and drug sensitivity in trypanosomes. Proc Natl Acad Sci U S A 112:9112–9117. https://doi.org/10.1073/pnas.1505411112.

15. Schnaufer A, Panigrahi AK, Panicucci B, Igo RP, Wirtz E, Salavati R, Stuart K. 2001. An RNA ligase essential for RNA editing and survival of the bloodstream form of Trypanosoma brucei. Science 291:2159–2162. https://doi.org/10.1126/science.1058955.

16. Huang CE, Cruz-Reyes J, Zhelonkina AG, O’Hearn S, Wirtz E, Sollner-Webb B. 2001. Roles for ligases in the RNA editing complex of Trypanosoma brucei: band IV is needed for U-deletion and RNA repair. EMBO J 20:4694–4703. https://doi.org/10.1093/emboj/20.17.4694.

17. Šubrtová K, Panicucci B, Ziková A. 2015. ATPaseTb2, a unique membrane-bound F1Fo-ATPase component, is essential in bloodstream and dyskinetoplastic trypanosomes. PLoS Pathog 11:e1004660. https://doi.org/10.1371/journal.ppat.1004660.

18. Trikin R, Doiron N, Hoffmann A, Haenni B, Jakob M, Schnaufer A, Schimanski B, Zuber B, Ochsenreiter T. 2016. TAC102 is a novel component of the mitochondrial genome segregation machinery in trypanosomes. PLoS Pathog 12:e1005586. https://doi.org/10.1371/journal.ppat.1005586.

19. Garipler G, Dunn CD. 2013. Defects associated with mitochondrial DNA damage can be mitigated by increased vacuolar pH in Saccharomyces cerevisiae. Genetics 194:285–290. https://doi.org/10.1534/genetics.113.149708.

20. Wirtz E, Leal S, Ochatt C, Cross GA. 1999. A tightly regulated inducible expression system for conditional gene knock-outs and dominant-negative genetics in Trypanosoma brucei. Mol Biochem Parasitol 99:89–101. https://doi.org/10.1016/S0166-6851(99)00002-X.